Literature DB >> 26973315

FDA and the safe and appropriate antibiotic use of fluoroquinolones.

Glenn S Tillotson1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26973315     DOI: 10.1016/S1473-3099(16)00051-7

Source DB:  PubMed          Journal:  Lancet Infect Dis        ISSN: 1473-3099            Impact factor:   25.071


× No keyword cloud information.
  5 in total

1.  In Vivo Pharmacodynamic Evaluation of Omadacycline (PTK 0796) against Streptococcus pneumoniae in the Murine Pneumonia Model.

Authors:  Alexander J Lepak; Miao Zhao; Karen Marchillo; Jamie VanHecker; David R Andes
Journal:  Antimicrob Agents Chemother       Date:  2017-04-24       Impact factor: 5.191

2.  Indications for Systemic Fluoroquinolone Therapy in Europe and Prevalence of Primary-Care Prescribing in France, Germany and the UK: Descriptive Population-Based Study.

Authors:  Daniel R Morales; Jim Slattery; Luis Pinheiro; Xavier Kurz; Karin Hedenmalm
Journal:  Clin Drug Investig       Date:  2018-10       Impact factor: 2.859

3.  Disease characteristics and management of hospitalised adolescents and adults with community-acquired pneumonia in China: a retrospective multicentre survey.

Authors:  Liang Chen; Fei Zhou; Hui Li; Xiqian Xing; Xiudi Han; Yiming Wang; Chunxiao Zhang; Lijun Suo; Jingxiang Wang; Guohua Yu; Guangqiang Wang; Xuexin Yao; Hongxia Yu; Lei Wang; Meng Liu; Chunxue Xue; Bo Liu; Xiaoli Zhu; Yanli Li; Ying Xiao; Xiaojing Cui; Lijuan Li; Timothy M Uyeki; Chen Wang; Bin Cao
Journal:  BMJ Open       Date:  2018-02-15       Impact factor: 2.692

4.  Efficacy and safety of delafloxacin, ceftaroline, ceftobiprole, and tigecycline for the empiric treatment of acute bacterial skin and skin structure infections: A network meta-analysis of randomized controlled trials.

Authors:  Abdullah A Alhifany; Nisrin Bifari; Yasser Alatawi; Saad U Malik; Thamer A Almangour; Ali F Altebainawi; Thamir M Alshammari; Amal F Alotaibi; Ahmad J Mahrous; Fahad S Alshehri; Ejaz Cheema
Journal:  Saudi Pharm J       Date:  2022-01-01       Impact factor: 4.562

Review 5.  Delafloxacin: Place in Therapy and Review of Microbiologic, Clinical and Pharmacologic Properties.

Authors:  Sarah C J Jorgensen; Nicholas J Mercuro; Susan L Davis; Michael J Rybak
Journal:  Infect Dis Ther       Date:  2018-03-31
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.